Article: Stop Putting All the Blame on PBMs
Jack Kemp Foundation's Ike Brannon and DePaul University's Tony LoSasso in a recent article published on Bloomberg Law say pinning [...]
Providers’ ‘Deeply Ingrained’ Model Disrupts Shift to Value
While providers claim a number of reasons for their reluctance to shift to risk-based deals, Numerof & Associates' Rita Numerof [...]
Frakt Outlines Major Study on Health Spending
Austin Frakt in a recent article highlights some of the key findings in a study published Monday, Jan. 6, in [...]
Pharma Execs Support New Commitment to Patients
A group of pharmaceutical executives has pledged its support for a renewed effort to put the patient first after signing [...]
Evidera White Paper Highlights PPI in Europe
A recent white paper by Evidera, "Patient Preferences in Health Technology Assessment in Europe: Recent Advances and Future Potential," spotlights [...]
Researchers Find ICER Makes ‘Modest’ Revisions Based on Comments
Tufts Medical Center researchers in a recent article published in Value in Health found that the Institute for Clinical and [...]
ICER Outlines Planned Review for Beta Thalassemia Treatments
The Institute for Clinical and Economic Review (ICER) on Monday released a new document outlining a planned review of LentiGlobin [...]
NPR Blog: Global Trends to Watch in 2020
NPR in a recent blog post highlights some key global trends to watch in 2020, including rising demand for humanitarian [...]
Using Innovative Data Analytics for Market Access
Dr. Patti Peeples, CEO of HealthEconomics.com, sat down with Walter Bouwmeester, Real-World Evidence and Data Analytics Lead in Europe, to discuss the use of data analytics to support multidimensional health economics and outcomes research (HEOR) in Europe.
Changing the Clinical Trial Paradigm for Rare and Orphan (R&O) Diseases using Real-World Evidence
Interview with Flora Sandra Siami, MPH. Vice President of Clinical Research, Regulatory Affairs, and Quality Assurance at HealthCore-NERI. Dr. Patti [...]
Benchmarking Survey: Can we reduce procurement time in HEOR & RWE?
As healthcare moves towards an increased focus on outcomes and value, health economics & outcomes research (HEOR) and real-world evidence [...]
Pharmacy benefit managers: a mechanism for containing costs or a contributor to rising drug prices?
While pharmaceutical companies are often the focus of conversations about high drug prices, more recently pharmacy benefit managers (PBMs) have [...]
CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, [...]
HEOR Salaries: Big Growth in Certain Sectors. Where Do You Stand?
2017 HEOR & Market Access Salaries show big growth in key areas of Pricing, Market Access, and HEOR-focused Medical Communications. [...]
Big Ideas for Big Data Analytics in Real-World Evidence: Insights from Dr. Rich Gliklich, CEO of OM1
Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Rich Gliklich, CEO of OM1, to discuss how big [...]
An Englishman in New York
Part I: A letter from America. by Professor Andrew Briggs "A cynic knows the price of everything but the [...]
A Case for Better Health Care Economics Education in the United States
Reynold W. (Pete) Mooney About a year ago I had an informal meeting with several CEO acquaintances. One [...]
How to Shine at an Online Career Fair
On Wednesday, January 20, 2016, HealthEconomics.Com is hosting their 5th Online Career Fair specifically for the HEOR, Market Access and [...]
Drug Pricing Value Assessment Methods in the United States: The National Pharmaceutical Council Viewpoint
Swarali Tadwalkar, MPHIntern Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the [...]
How Much Do HEOR Professionals Make?
I wish the buck stopped here. I could use a few. That sounds a little like a Henny Youngman one-liner, [...]
How Should Health Care Providers Measure and Market the “Value” of their Services?
John Schneider, Ph.D There was a time when we did not spend a lot of time worrying about [...]
Integration of Novel Diagnostics into Clinical Practice
By John Schneider, Ph.D Similar to drug and device markets, a critical part of the success of novel [...]
Removing Bias from HEOR: Standardizing the Costs of Adverse Events
By Jim Davis What are the total costs of prescribing a particular drug? At its core, all health [...]
Choose a Job You Love, and You’ll Never Have to Work a Day in Your Life!
We should all be so lucky to have a job we love. Do you? If you're an employer, don't you [...]
21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety
By Jim Davis As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. [...]